67-kDa laminin receptor-dependent Protein Phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance

Shuntaro Tsukamoto, Yuhui Huang, Daisuke Umeda, Shuhei Yamada, Shuya Yamashita, Motofumi Kumazoe, Yoonhee Kim, Motoki Murata, Koji Yamada, Hirofumi Tachibana

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The Ras/Raf/MEK/ERK pathway has been identified as a major, druggable regulator of melanoma. Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, resulting in constitutive melanoma hyperproliferation. A selective BRAF inhibitor showed remarkable clinical activity in patients with mutated BRAF. Unfortunately, most patients acquire resistance to the BRAF inhibitor, highlighting the urgent need for new melanoma treatment strategies. Green tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG) inhibits cell proliferation independently of BRAF inhibitor sensitivity, suggesting that increased understanding of the anti-melanoma activity of EGCG may provide a novel therapeutic target. Here, by performing functional genetic screening, we identified protein phosphatase 2A (PP2A) as a critical factor in the suppression of melanoma cell proliferation. We demonstrated that tumor-overexpressed 67-kDa laminin receptor (67LR) activates PP2A through adenylate cyclase/cAMP pathway eliciting inhibitions of oncoproteins and activation of tumor suppressor Merlin. Activating 67LR/PP2A pathway leading to melanomaspecific mTOR inhibition shows strong synergy with the BRAF inhibitor PLX4720 in the drug-resistant melanoma. Moreover, SET, a potent inhibitor of PP2A, is overexpressed on malignant melanoma. Silencing of SET enhances 67LR/PP2A signaling. Collectively, activation of 67LR/PP2A signaling may thus be a novel rational strategy for melanoma-specific treatment.

Original languageEnglish
Pages (from-to)32671-32681
Number of pages11
JournalJournal of Biological Chemistry
Volume289
Issue number47
DOIs
Publication statusPublished - Nov 21 2014

Fingerprint

Laminin Receptors
Protein Phosphatase 2
Drug Resistance
Melanoma
Chemical activation
Pharmaceutical Preparations
Cell proliferation
Tumors
Neurofibromin 2
Oncogene Proteins
Mitogen-Activated Protein Kinase Kinases
Polyphenols
Adenylyl Cyclases
Cell Proliferation
Screening
MAP Kinase Signaling System
Genetic Testing
Tea
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

67-kDa laminin receptor-dependent Protein Phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance. / Tsukamoto, Shuntaro; Huang, Yuhui; Umeda, Daisuke; Yamada, Shuhei; Yamashita, Shuya; Kumazoe, Motofumi; Kim, Yoonhee; Murata, Motoki; Yamada, Koji; Tachibana, Hirofumi.

In: Journal of Biological Chemistry, Vol. 289, No. 47, 21.11.2014, p. 32671-32681.

Research output: Contribution to journalArticle

Tsukamoto, Shuntaro ; Huang, Yuhui ; Umeda, Daisuke ; Yamada, Shuhei ; Yamashita, Shuya ; Kumazoe, Motofumi ; Kim, Yoonhee ; Murata, Motoki ; Yamada, Koji ; Tachibana, Hirofumi. / 67-kDa laminin receptor-dependent Protein Phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance. In: Journal of Biological Chemistry. 2014 ; Vol. 289, No. 47. pp. 32671-32681.
@article{213c66d8a6424b5cb2b670a0f9cf8ec4,
title = "67-kDa laminin receptor-dependent Protein Phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance",
abstract = "The Ras/Raf/MEK/ERK pathway has been identified as a major, druggable regulator of melanoma. Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, resulting in constitutive melanoma hyperproliferation. A selective BRAF inhibitor showed remarkable clinical activity in patients with mutated BRAF. Unfortunately, most patients acquire resistance to the BRAF inhibitor, highlighting the urgent need for new melanoma treatment strategies. Green tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG) inhibits cell proliferation independently of BRAF inhibitor sensitivity, suggesting that increased understanding of the anti-melanoma activity of EGCG may provide a novel therapeutic target. Here, by performing functional genetic screening, we identified protein phosphatase 2A (PP2A) as a critical factor in the suppression of melanoma cell proliferation. We demonstrated that tumor-overexpressed 67-kDa laminin receptor (67LR) activates PP2A through adenylate cyclase/cAMP pathway eliciting inhibitions of oncoproteins and activation of tumor suppressor Merlin. Activating 67LR/PP2A pathway leading to melanomaspecific mTOR inhibition shows strong synergy with the BRAF inhibitor PLX4720 in the drug-resistant melanoma. Moreover, SET, a potent inhibitor of PP2A, is overexpressed on malignant melanoma. Silencing of SET enhances 67LR/PP2A signaling. Collectively, activation of 67LR/PP2A signaling may thus be a novel rational strategy for melanoma-specific treatment.",
author = "Shuntaro Tsukamoto and Yuhui Huang and Daisuke Umeda and Shuhei Yamada and Shuya Yamashita and Motofumi Kumazoe and Yoonhee Kim and Motoki Murata and Koji Yamada and Hirofumi Tachibana",
year = "2014",
month = "11",
day = "21",
doi = "10.1074/jbc.M114.604983",
language = "English",
volume = "289",
pages = "32671--32681",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "47",

}

TY - JOUR

T1 - 67-kDa laminin receptor-dependent Protein Phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance

AU - Tsukamoto, Shuntaro

AU - Huang, Yuhui

AU - Umeda, Daisuke

AU - Yamada, Shuhei

AU - Yamashita, Shuya

AU - Kumazoe, Motofumi

AU - Kim, Yoonhee

AU - Murata, Motoki

AU - Yamada, Koji

AU - Tachibana, Hirofumi

PY - 2014/11/21

Y1 - 2014/11/21

N2 - The Ras/Raf/MEK/ERK pathway has been identified as a major, druggable regulator of melanoma. Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, resulting in constitutive melanoma hyperproliferation. A selective BRAF inhibitor showed remarkable clinical activity in patients with mutated BRAF. Unfortunately, most patients acquire resistance to the BRAF inhibitor, highlighting the urgent need for new melanoma treatment strategies. Green tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG) inhibits cell proliferation independently of BRAF inhibitor sensitivity, suggesting that increased understanding of the anti-melanoma activity of EGCG may provide a novel therapeutic target. Here, by performing functional genetic screening, we identified protein phosphatase 2A (PP2A) as a critical factor in the suppression of melanoma cell proliferation. We demonstrated that tumor-overexpressed 67-kDa laminin receptor (67LR) activates PP2A through adenylate cyclase/cAMP pathway eliciting inhibitions of oncoproteins and activation of tumor suppressor Merlin. Activating 67LR/PP2A pathway leading to melanomaspecific mTOR inhibition shows strong synergy with the BRAF inhibitor PLX4720 in the drug-resistant melanoma. Moreover, SET, a potent inhibitor of PP2A, is overexpressed on malignant melanoma. Silencing of SET enhances 67LR/PP2A signaling. Collectively, activation of 67LR/PP2A signaling may thus be a novel rational strategy for melanoma-specific treatment.

AB - The Ras/Raf/MEK/ERK pathway has been identified as a major, druggable regulator of melanoma. Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, resulting in constitutive melanoma hyperproliferation. A selective BRAF inhibitor showed remarkable clinical activity in patients with mutated BRAF. Unfortunately, most patients acquire resistance to the BRAF inhibitor, highlighting the urgent need for new melanoma treatment strategies. Green tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG) inhibits cell proliferation independently of BRAF inhibitor sensitivity, suggesting that increased understanding of the anti-melanoma activity of EGCG may provide a novel therapeutic target. Here, by performing functional genetic screening, we identified protein phosphatase 2A (PP2A) as a critical factor in the suppression of melanoma cell proliferation. We demonstrated that tumor-overexpressed 67-kDa laminin receptor (67LR) activates PP2A through adenylate cyclase/cAMP pathway eliciting inhibitions of oncoproteins and activation of tumor suppressor Merlin. Activating 67LR/PP2A pathway leading to melanomaspecific mTOR inhibition shows strong synergy with the BRAF inhibitor PLX4720 in the drug-resistant melanoma. Moreover, SET, a potent inhibitor of PP2A, is overexpressed on malignant melanoma. Silencing of SET enhances 67LR/PP2A signaling. Collectively, activation of 67LR/PP2A signaling may thus be a novel rational strategy for melanoma-specific treatment.

UR - http://www.scopus.com/inward/record.url?scp=84911898978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911898978&partnerID=8YFLogxK

U2 - 10.1074/jbc.M114.604983

DO - 10.1074/jbc.M114.604983

M3 - Article

C2 - 25294877

AN - SCOPUS:84911898978

VL - 289

SP - 32671

EP - 32681

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 47

ER -